| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | EIF-5A; EIF5A1; eIF5AI |
| Entrez GeneID | 1984 |
| clone | 4E10G8 |
| WB Predicted band size | 16.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human EIF5A (AA: full(1-154)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是模拟生成的关于EIF5A抗体的参考文献示例(非真实文献，仅供格式参考)：
1. **标题**：*EIF5A Hypusination in Cancer: Role of Specific Antibody Detection in Tumor Progression*
**作者**：Lee, J., et al.
**摘要**：研究通过开发特异性识别hypusine修饰EIF5A的抗体，发现其在多种癌症组织中的表达上调，并与肿瘤转移及患者预后不良显著相关。
2. **标题**：*Development of a Monoclonal Antibody for EIF5A and Its Application in Neurodegenerative Disease Models*
**作者**：Smith, R., & Zhang, H.
**摘要**：报道了一种高特异性抗EIF5A单克隆抗体的制备，并利用该抗体在小鼠阿尔茨海默病模型中观察到EIF5A在神经元中的异常聚集现象。
3. **标题**：*EIF5A2 Isoform-Specific Antibody Reveals Distinct Roles in Epithelial-Mesenchymal Transition*
**作者**：Chen, L., et al.
**摘要**：通过构建针对EIF5A2亚型的抗体，揭示了该亚型在EMT(上皮-间质转化)中的关键作用，为靶向治疗提供了潜在标记物。
4. **标题**：*Antibody-Based Inhibition of EIF5A Hypusination Suppresses Inflammatory Responses in Macrophages*
**作者**：Garcia, M., et al.
**摘要**：利用抗EIF5A抗体阻断hypusine修饰通路，发现可显著降低巨噬细胞的炎症因子分泌，提示其在炎症性疾病中的治疗潜力。
(注：以上文献为模拟生成，实际引用需查询真实数据库如PubMed、Web of Science等。)
**Background of EIF5A Antibodies**
Eukaryotic translation initiation factor 5A (EIF5A), initially identified as a translation initiation factor, is now recognized to play a broader role in mRNA translation elongation, particularly for polyproline-rich sequences. A defining feature of EIF5A is its unique post-translational modification called hypusination, where a spermidine-derived hypusine residue is enzymatically added to a conserved lysine. This modification, catalyzed by deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH), is critical for EIF5A’s functional activation. EIF5A exists in two isoforms, EIF5A1 (ubiquitously expressed) and EIF5A2 (tissue-specific, often linked to cancer), both implicated in cellular processes like proliferation, apoptosis, and stress responses.
Antibodies targeting EIF5A are essential tools for studying its expression, localization, and hypusination status. They enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Specific antibodies may distinguish between isoforms or hypusinated/non-hypusinated forms, aiding research into diseases such as cancer, neurodegenerative disorders, and viral infections, where EIF5A dysregulation is observed. For example, EIF5A2 overexpression correlates with tumor progression, while hypusination defects are linked to neurodevelopmental conditions.
Researchers must validate EIF5A antibodies for specificity, as cross-reactivity between isoforms or unmodified/modified forms can lead to inaccurate interpretations. These antibodies are pivotal in elucidating EIF5A’s multifaceted roles in health and disease.
×
